Oncolytics Biotech Inc. (TSE:ONC - Get Free Report) shot up 24.1% on Wednesday . The stock traded as high as C$1.72 and last traded at C$1.70. 892,106 shares traded hands during trading, an increase of 556% from the average session volume of 135,968 shares. The stock had previously closed at C$1.37.
Wall Street Analyst Weigh In
Separately, Jones Trading cut Oncolytics Biotech from a "strong-buy" rating to a "hold" rating in a report on Friday, May 16th.
View Our Latest Report on Oncolytics Biotech
Oncolytics Biotech Trading Up 6.0%
The company has a quick ratio of 8.86, a current ratio of 2.99 and a debt-to-equity ratio of 11.75. The stock has a fifty day simple moving average of C$0.82 and a 200 day simple moving average of C$0.94. The firm has a market capitalization of C$123.32 million, a P/E ratio of -4.46 and a beta of 1.35.
About Oncolytics Biotech
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
See Also
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
